Clyde M. Ofner III, Ph.D., has been a professor of pharmaceutics in the Philadelphia College of Pharmacy since 1987. His responsibilities include teaching courses in pharmacy, pharmaceutical chemistry and pharmaceutical technology, as well as in the pharmaceutics graduate program. Research in his group is focused on macromolecular drug delivery for tumor therapy. There are several potential advantages that a macromolecular conjugate of an anticancer drug may have compared to the free drug. These include higher maximum tolerated doses, an enhanced local effect, and reduced side effect toxicities. He is particularly interested in the role of molecular weight and other properties using a biodegradable carrier at the cellular and tumor level. Current research projects are aimed at:
Characterizing the ability of a high molecular weight biodegradable carrier to extend circulation time of a conjugate (gelatin/doxorubicin, G-DOX) followed by enhanced tumor accumulation and intracellular uptake
Determining intracellular mechanistic differences between the free drug and G-DOX
Design and evaluation of high dose methotrexate effects using soluble gelatin-methotrexate conjugates and microspheres
Dr. Ofner has directed the research of about two dozen undergraduate and graduate students which has involved gelatin, a natural product, and includes anticancer-gelatin conjugates for soluble and microsphere delivery, and release of macromolecules from implantable and biodegradable gelatin hydrogels. One area of current research (NIH-funded) focuses on exploring enhanced cellular uptake of anticancer-gelatin conjugates to increase drug effectiveness and reduce toxic side effects of a drug. He has about 50 publications of research abstracts, research articles and book chapters. He received the FDA Commissioner’s Special Citation for his work on the Gelatin Capsule Working Group of the FDA (1995-98). He was president of the USP chapter of Sigma Xi (The Scientific Research Society) and has been an officer of the Philadelphia Pharmaceutical Forum, a discussion group of the American Association of Pharmaceutical Scientists since 1989.
Dr. Ofner is a licensed pharmacist in the state of Pennsylvania, and is also a member of the honor society of pharmacy (Rho Chi), the American Association of Colleges of Pharmacy and the American Pharmaceutical Association.
B.S., Temple University
PhD, Temple University
C.S. Chen and C.M. Ofner III. "The Effect of Charge, Drug Load, and Molecular Weight of Gelatin-Methotrexate Conjugates on Cytoxicity in HL60 Leukemia Cells." Pharm. Res., 26:338-345 (2009).
D.C. Wu, G. Williams, M. Tasheva, B. Rhodes, C.M. Ofner III. "Preliminary Evaluation of pH Controlled Drug Release from a Gelatin – Doxorubicin Conjugate." The AAPS Journal, 11(S2): Abstract #T3409, 2009.
C.M. Ofner III, C.S. Chen, K. Pica. "Macromolecular Conjugates for Passive Tumor Targeting: In Vitro Studies with a Gelatin-Methotrexate Conjugate." EHRLICH II-2nd World Conference on Magic Bullets, Nurnberg, Germany, October 4, 2008.
R. Desai, N. Patel, C.S. Chen, C.M. Ofner III. "Cytostatic and Cytocidal Effects of a Gelatin-Methothrexate Conjugate and Free Methotraxate on HL60 Leukemia Cells." The AAPS Journal, 9(S2): Abstract T3366 (2007).
C.M. Ofner III. "Soluble Macromolecular Conjugates for Passive Tumor Targeting." Philadelphia Pharmaceutical Forum, North Wales, P.A., January 11, 2007
C.M. Ofner III, K. Pica, B.J. Bowman, C.S Chen. "Growth Inhibition, Degradation, and Methotrexate Release Studies of Gelatin/Methotrexate Conjugates." Int.J.Pharm., 308: 90-99 (2006)
J.W. Mwangi and CM Ofner III. "Crosslinked Gelatin Matrices: Release of a Random Coil Macromolecular Solute." Int. J. Pharm. 278:319-327 (2004)
C.M. Ofner III, Y.E. Zhang, V.C. Jobeck, B.J. Bowman. "Crosslinking Studies in Gelatin Capsules Treated with Formaldehyde and in Capsules Exposed to Elevated Temperature and Humidity." J. Pharm. Sci., 90(1):79-87 (2001).
Natural polymer conjugates of drugs for cellular and tumor delivery
Controlled drug release from proteinaceous microspheres
Crosslinking in gelatin used in capsule shells and subsequent partial release of drug contents
Gelatin hydrogels as biodegradable implants to deliver small and macromolecular drugs
Drug delivery research using macromolecular conjugates of anticancer agents